Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
3.570
+0.210 (6.25%)
Dec 20, 2024, 4:00 PM EST - Market closed
Sight Sciences Employees
Sight Sciences had 214 employees as of December 31, 2023. The number of employees decreased by 36 or -14.40% compared to the previous year.
Employees
214
Change (1Y)
-36
Growth (1Y)
-14.40%
Revenue / Employee
$371,696
Profits / Employee
-$235,290
Market Cap
181.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 214 | -36 | -14.40% |
| Dec 31, 2022 | 250 | 38 | 17.92% |
| Dec 31, 2021 | 212 | 43 | 25.44% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| InfuSystem Holdings | 516 |
| Coherus BioSciences | 306 |
| Alector | 244 |
| Lyell Immunopharma | 224 |
| Nektar Therapeutics | 137 |
| BrainsWay | 134 |
| EUDA Health Holdings | 106 |
| KORU Medical Systems | 82 |
SGHT News
- 2 days ago - Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options - GlobeNewsWire
- 4 weeks ago - Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Top 3 Health Care Stocks You'll Regret Missing In November - Benzinga
- 2 months ago - Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 - GlobeNewsWire
- 2 months ago - Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial - GlobeNewsWire
- 4 months ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript - Seeking Alpha